Latest News Releases

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces revised strategy

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta018/20.02.2024/13:45) - Biofrontera AG today entered into an agreement with Biofrontera Inc. to modify the business relationship between the two companies. Biofrontera AG will focus on capitalizing its existing projects and know-how, while research and development will no longer be a core part of its activities. This revised strategy and the amended agreement with Biofrontera AG's largest customer, Biofrontera Inc., will have a significant impact on the structure of revenues and costs, both of which will be reduced. Biofrontera AG will provide new guidance for 2024 in due course.


emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate

[ source: ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8F).